Type 2 diabetes, which usually arises in adulthood and often stems from poor diet, lack of exercise and obesity - accounts for more than 90 per cent of diabetes cases.
Timothy Kieffer, a professor in the department of cellular and physiological sciences at the University of British Columbia, and scientists from BetaLogics simulated Type 2 diabetes in mice by putting them on a high-fat, high-calorie diet for several weeks.
Kieffer's team then surgically implanted pancreatic-like cells that had been grown in the laboratory from human stem cells.
In contrast, a group of mice with simulated Type 2 diabetes that received the drugs but not the transplants remained glucose-intolerant.
"Being able to reduce spikes in blood sugar levels is important because evidence suggests it's those spikes that do a lot of the damage - increasing risks for blindness, heart attack, and kidney failure," said Kieffer, a member of UBC's Life Sciences Institute.
"Their weight loss was intriguing, because some of the common diabetes therapies often lead to weight gain. We need to do more studies to understand how the cell transplants lead to weight loss," Kieffer said.
The study was published in the journal Stem Cell Reports.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
